Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US.

Saved in:
Bibliographic Details
Title: Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US.
Authors: Tieu HV; Laboratory of Infectious Disease Prevention, Lindsley F. Kimball Research Institute, New York Blood Center, USA; Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, USA., Karuna S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Huang Y; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA., Sobieszczyk ME; Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, USA., Zheng H; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Tomaras GD; Department of Global Health, University of Washington, Seattle, WA, USA., Montefiori DC; Department of Global Health, University of Washington, Seattle, WA, USA., Shen M; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., DeRosa S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Cohen K; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Isaacs MB; Division of Refugee Health, Administration for Children and Families, Department of Health and Human Services, USA., Regenold S; Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA., Heptinstall J; Department of Surgery, Duke University, Durham, NC, USA., Seaton KE; Department of Surgery, Duke University, Durham, NC, USA., Sawant S; Department of Surgery, Duke University, Durham, NC, USA., Furch B; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Pensiero M; Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA., Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Bar KJ; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: bark@pennmedicine.upenn.edu.
Corporate Authors: HVTN 122 Study Team
Source: Vaccine [Vaccine] 2023 Oct 06; Vol. 41 (42), pp. 6309-6317. Date of Electronic Publication: 2023 Sep 09.
Publication Type: Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial; Research Support, N.I.H., Extramural
Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1873-2518
DOI:10.1016/j.vaccine.2023.07.046